Covidien

The first patient has been recruited to a new clinical trial, which represents one of the largest global studies to examine the effectiveness of an advanced mechanical treatment in stroke care.

Covidien is trumpeting the five-year results of its ClosureFast™ Long-Term European Multi-Centre Study in patients with Chronic Venous Insufficiency. 92% of patients still had effective occlusion of target vessels after five years, supporting the claim that the treatment is durable in the longer term.

Covidien has announced a definitive agreement to acquire CV Ingenuity. The companies expect to complete the acquisition in the first calendar quarter of 2013.

GE Healthcare will be integrating Covidien’s Nellcor™ pulse oximetry with OxiMax™ technology into its Giraffe® and Panda® infant warmers, in a move which will help clinicians safely monitor infants for life-threatening and respiratory complications.

Covidien’s eV3 subsidiary business brought with it the Pipeline embolisation device when it was acquired. While the device shows encouraging results in patients with certain types of difficult-to-treat brain aneurysms, a new report suggests there are also reasons for some caution over fatal bleeds.

Covidien must be hoping surgeons will see the benefit of simplicity in its new meniscal repair device which has the retro feel of the twin needle gizmos we first saw twenty years ago.

Study confirms effectiveness of directional Atherectomy with SilverHawk ™ and TurboHawk ™ Devices as a frontline therapy when treating PAD

Covidien has announced U.S. FDA 510(k) clearance and CE Mark approval for its next generation of Nellcor™ Bedside Respiratory Patient Monitoring system.

Covidien is showcasing some of its most innovative surgical products at the American College of Surgeons (ACS) annual clinical congress being held at McCormick Place in Chicago this week. Key featured products include the new Sonicision™ ultrasonic incision and hemostasis device as well as the company’s iDrive™ Ultra powered stapling system.

Certain of Covidien’s Shiley, reusable cannula, cuffed trachoestomy tubes appear to have leakage and disconnection issues, which has lead to the UK’s MHRA issuing a Medical Device Alert.

Covidien has announced that it has received 510(k) clearance from the U.S. FDA for its LigaSure™ curved, small jaw, open sealer/divider surgical instrument to be used in ear, nose and throat (ENT) procedures.

Covidien says its newly FDA cleared device is the world’s only fully powered reusable surgical EndoStapling platform and claims it sets new standards in precision during surgery.

Ageing population, improved screening and new treatments will drive GI Endoscopy market in U.S.A

Covidien is conducting a voluntary recall of certain production lots of the DGPHP RFA High-Power Single Use Grounding Pads and Cool-tip™ RFA Electrode Kits that contain DGPHP RFA High-Power Single Use Grounding Pads.

As is often the case a company’s voluntary recall has morphed into the FDA Class 1 variety. This time it’s Covidien’s Shiley Adult Tracheostomy Tubes which have reportedly suffered disconnection and leakage.

Covidien has confirmed that it notified customers on July 18, 2012, about a voluntary global recall of certain lots of its Shiley™ reusable cannula, cuffed adult tracheostomy tubes, size 8. This action was in response to reports of volume leakage and/or disconnection between the inner and outer cannulae.